Day One Biopharmaceuticals (NASDAQ:DAWN) Earns Buy Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Day One Biopharmaceuticals (NASDAQ:DAWN) in a research note released on Thursday,Benzinga reports. They currently have a $36.00 price target on the stock.

A number of other research firms have also commented on DAWN. Bank of America reduced their price target on shares of Day One Biopharmaceuticals from $28.00 to $25.00 and set a “buy” rating for the company in a research report on Tuesday, January 7th. The Goldman Sachs Group reduced their target price on Day One Biopharmaceuticals from $39.00 to $27.00 and set a “buy” rating for the company in a research report on Tuesday, March 25th. Needham & Company LLC reaffirmed a “buy” rating and issued a $32.00 price target on shares of Day One Biopharmaceuticals in a report on Wednesday, February 26th. Wedbush reiterated an “outperform” rating and set a $32.00 price target on shares of Day One Biopharmaceuticals in a research report on Wednesday, February 26th. Finally, JPMorgan Chase & Co. decreased their price objective on shares of Day One Biopharmaceuticals from $39.00 to $34.00 and set an “overweight” rating on the stock in a research report on Wednesday, March 5th. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Day One Biopharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $32.29.

Day One Biopharmaceuticals Stock Down 6.4 %

Shares of NASDAQ DAWN opened at $7.22 on Thursday. The company has a market cap of $731.78 million, a P/E ratio of -7.01 and a beta of -1.24. Day One Biopharmaceuticals has a 52 week low of $7.06 and a 52 week high of $18.07. The business has a 50-day simple moving average of $10.13 and a two-hundred day simple moving average of $12.39.

Day One Biopharmaceuticals (NASDAQ:DAWN) last released its quarterly earnings data on Tuesday, February 25th. The company reported ($0.69) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.34). The firm had revenue of $29.21 million for the quarter, compared to the consensus estimate of $27.11 million. Equities research analysts anticipate that Day One Biopharmaceuticals will post -0.72 EPS for the current year.

Insider Transactions at Day One Biopharmaceuticals

In related news, General Counsel Adam Dubow sold 4,646 shares of the business’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $11.96, for a total value of $55,566.16. Following the completion of the sale, the general counsel now owns 39,602 shares in the company, valued at $473,639.92. The trade was a 10.50 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Jeremy Bender sold 12,048 shares of the stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total transaction of $144,094.08. Following the transaction, the chief executive officer now owns 128,015 shares in the company, valued at $1,531,059.40. The trade was a 8.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 21,064 shares of company stock worth $251,925. 8.40% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Day One Biopharmaceuticals

A number of large investors have recently added to or reduced their stakes in the business. Virtus ETF Advisers LLC boosted its position in Day One Biopharmaceuticals by 7.1% during the fourth quarter. Virtus ETF Advisers LLC now owns 27,296 shares of the company’s stock valued at $346,000 after buying an additional 1,805 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Day One Biopharmaceuticals by 5.6% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 35,843 shares of the company’s stock valued at $454,000 after acquiring an additional 1,894 shares during the period. GF Fund Management CO. LTD. bought a new position in Day One Biopharmaceuticals during the 4th quarter worth approximately $27,000. China Universal Asset Management Co. Ltd. increased its stake in Day One Biopharmaceuticals by 11.4% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 21,383 shares of the company’s stock worth $271,000 after purchasing an additional 2,180 shares during the period. Finally, R Squared Ltd bought a new stake in Day One Biopharmaceuticals in the fourth quarter valued at approximately $31,000. Hedge funds and other institutional investors own 87.95% of the company’s stock.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.